These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 5311030)

  • 1. Long-acting thyroid stimulator in thyrotoxic monozygous twins.
    Priest WM
    Br Med J; 1970 Jul; 3(5716):205. PubMed ID: 5311030
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between the long-acting thyroid stimulator and the thyroid microsomal antibody.
    Bonnyns M; Vanhaelst L
    J Endocrinol; 1969 Jan; 43(1):125-6. PubMed ID: 4886576
    [No Abstract]   [Full Text] [Related]  

  • 3. LATS protector, the human thyroid stimulator.
    Adams DD
    N Z Med J; 1975 Jan; 81(531):22-3. PubMed ID: 1055310
    [No Abstract]   [Full Text] [Related]  

  • 4. [Studies on the problem of a relationship between the occurrence of thyroid antibodies and LATS in hyperthyreosis].
    Weissbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W; Bindeballe W
    Med Klin; 1966 Dec; 61(52):2062-3. PubMed ID: 5999210
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of long acting thyroid stimulator in neonatal thyrotoxicosis.
    Maisey MN; Stimmler L
    Clin Endocrinol (Oxf); 1972 Jan; 1(1):81-90. PubMed ID: 4677121
    [No Abstract]   [Full Text] [Related]  

  • 6. Thyrotoxicosis and Hashimoto goitre in a pair of monozygotic twins with serum long-acting thyroid stimulator.
    Jayson MI; Doniach D; Benhamou-Glynn N; Roitt IM; el Kabir DJ
    Lancet; 1967 Jul; 2(7505):15-8. PubMed ID: 4165437
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathogenesis of iodine-induced thyrotoxicosis: studies in northern Tasmania.
    Vidor GI; Stewart JC; Wall JR; Wangel A; Hetzel BS
    J Clin Endocrinol Metab; 1973 Dec; 37(6):901-9. PubMed ID: 4753432
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-acting thyroid stimulator in euthyroid relatives of thyrotoxic patients.
    Wall JR; Good BF; Hetzel BS
    Lancet; 1969 Nov; 2(7629):1024-6. PubMed ID: 4187540
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes in LATS and other thyoid autoantibody levels with therapy.
    Kilpatrick JA
    N Z Med J; 1974 Dec; 80(529):495-6. PubMed ID: 4532201
    [No Abstract]   [Full Text] [Related]  

  • 10. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
    Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
    J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of an in vitro binding reaction between thyroid microsomes and long acting thyroid stimulator globulin (LATS). I. Development of solid-state competitive binding radioassay methods for measurement of antimicrosomal and antithyroglobuin antibodies.
    Mori T; Fisher J; Kriss JP
    J Clin Endocrinol Metab; 1970 Aug; 31(2):119-33. PubMed ID: 4193195
    [No Abstract]   [Full Text] [Related]  

  • 12. The long-acting thyroid stimulator.
    Munro DS
    Curr Top Exp Endocrinol; 1971; 1():175-98. PubMed ID: 4350824
    [No Abstract]   [Full Text] [Related]  

  • 13. [Long-acting thyroid stimulator (LATS) in thyroid gland diseases and its relationship to the thyroid gland antibodies].
    Weissbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W; Bindeballe W
    Schweiz Med Wochenschr; 1967 Jul; 97(28):898-904. PubMed ID: 5587446
    [No Abstract]   [Full Text] [Related]  

  • 14. [LATS and thyroid antibody level in the blood in Basedow's disease].
    Földes J; Takó J; Bános C; Gesztesi E; Varga I
    Orv Hetil; 1968 Aug; 109(33):1799-804. PubMed ID: 5714825
    [No Abstract]   [Full Text] [Related]  

  • 15. Pituitary-thyroid function in thyrotoxic patients in relation to long-acting thyroid stimulator (LATS) levels.
    Fukuchi M; Matsuoka T; Inoue T; Miyai K; Kumahara Y
    Acta Endocrinol (Copenh); 1970 Dec; 65(4):577-82. PubMed ID: 5536685
    [No Abstract]   [Full Text] [Related]  

  • 16. Neonatal transient thyrotoxicosis resulting from maternal TSH-binding inhibitor immunoglobulins.
    Yagi H; Takeuchi M; Nagashima K; Suzuki S; Kuroume T; Iida Y; Konishi J; Endo K
    J Pediatr; 1983 Oct; 103(4):591-3. PubMed ID: 6137525
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cytogenetic studies in patients with thyroiditis and LATS and antibody-positive hyperthyroidism].
    Tolksdorf M; Schemmel K; Mühlenstedt D; Uthgenannt H; Müller W
    Schweiz Med Wochenschr; 1969 Jul; 99(30):1082-5. PubMed ID: 5351142
    [No Abstract]   [Full Text] [Related]  

  • 18. [The long-acting thyroid stimulator (LATS) in untreated and I-131 treated hyperthyreoses, following total thyroidectomy, as well as its relation to thyroid antibodies].
    Ziemke A; Weisbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W
    Klin Wochenschr; 1968 Oct; 46(19):1025-7. PubMed ID: 5727481
    [No Abstract]   [Full Text] [Related]  

  • 19. Relation between thyroid function and serum levels of long-acting thyroid stimulator.
    Davis JC; Hipkin LJ; Summers VK; Gimlette TM
    Acta Endocrinol (Copenh); 1975 Jul; 79(3):451-8. PubMed ID: 1173501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
    Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
    J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.